Posted by
Arlo Fitzpatrick
Novo Nordisk Stock Drops 6% After Alzheimer’s Trial Failure, But Bernstein Stays Bullish on DKK540 Target
Novo Nordisk shares fell 6% after Ozempic failed an Alzheimer’s trial, but Bernstein analyst Florent Cespedes maintained a DKK540 price target, citing strong earnings, Metsera acquisition, and obesity drug momentum.